Schering-Plough Announces FDA Approval of Saphris (asenapine)

Schering-Plough Announces FDA Approval of Saphris (asenapine)
August 14, 2009
KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation today announced that the U.S. Food and Drug Administration
(FDA) has approved Saphris (asenapine) sublingual tablets for acute
treatment of schizophrenia in adults and acute treatment of manic or
mixed episodes associated with bipolar I disorder with or without
psychotic features in adults. Saphris can be used as a first-line
treatment and is the first psychotropic drug to receive initial
approval for both...